Good Life Meds

Medications offered

As listed on the provider’s own site. Whether a product is FDA-approved or compounded is the single most important distinction here — we explain why.

• Compounded semaglutideCompounded · not FDA-approved
• Compounded tirzepatide (GLP-1/GIP)Compounded · not FDA-approved

What they publish

Good Life Meds publishes 6 of 12 standard terms. Fields marked “not publicly disclosed” were not stated on the pages we captured, and we have not filled those gaps with assumptions. Compare disclosure across providers

Membership / programme fee

None — states no membership requirements and no additional fees (as published)

Medication cost

Compounded semaglutide published at $199 for a one-month supply; compounded tirzepatide at $297 monthly, $599 for a three-month supply and $822 quarterly. States the price is the same at every dose level. A $100 off promotion was displayed at capture (as published)

Introductory offer

Advertised $100 off at capture.

Insurance

Not publicly disclosed on the pages we captured.

HSA / FSA

Not publicly disclosed on the pages we captured.

Consultation process

Medical intake reviewed by a licensed provider who confirms the medication is appropriate before it is prescribed. States all prescriptions require physician approval.

Eligibility

Clinical criteria such as a BMI threshold were not published on the pages we captured.

Lab work

Not publicly disclosed on the pages we captured.

Pharmacy fulfilment

States medication is sourced entirely from US-based, state-licensed pharmacies described as following strict pharmaceutical standards. The pharmacies are not named.

Shipping

States medication is delivered to your door at what it describes as an accessible price with no hidden fees.

Support services

Not publicly disclosed on the pages we captured.

Cancellation

Cancellation terms were not published on the pages we captured.

Refunds

States that if a prescription is denied for any reason you will not be charged.

What stands out

• States the price is the same at every dose level for both molecules, so titration does not raise the bill.
• Commits that a denied prescription incurs no charge — a clearer position than the many competitors that take payment before clinical review and publish nothing about what happens next.
• Publishes both monthly and multi-month figures for tirzepatide, including a $599 three-month supply and an $822 quarterly option, though the relationship between those two is not explained.
• Sells compounded tirzepatide as a 'GLP-1 + GIP' formulation described as custom-formulated to support weight loss, metabolic health and energy — the energy claim suggests an added ingredient that is not itemised.
• The pharmacies are not named despite the emphasis on US licensing.
• No clinical criteria, lab requirement or cancellation terms are published.
• $199 and $297 sit in the middle of the compounded market rather than at the cheap end.

Questions to ask before you pay

These are things we could not settle from published pages, or that we think are easy to misread. Get answers in writing.

• What is the difference between the $599 three-month supply and the $822 quarterly option?
• The tirzepatide is described as boosting energy. What is added to it, and why?
• Which US pharmacy compounds the medication, and is it a 503A or 503B?
• What clinical criteria apply, and is lab work expected?
• No cancellation policy is published for the multi-month plans.
• Compounded medication is not FDA-approved. Do you understand what that means for oversight and recourse?

Frequently asked